Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 383Carcinoma, Renal Cell 210Urinary Bladder Neoplasms 117Carcinoma, Non-Small-Cell Lung 99Melanoma 78Kidney Neoplasms 74Carcinoma, Transitional Cell 73Neoplasm Metastasis 72Ovarian Neoplasms 71Breast Neoplasms 69Neoplasms 64Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 50Stomach Neoplasms 49Uterine Cervical Neoplasms 44Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 39Lung Neoplasms 35Esophageal Neoplasms 32Non-Muscle Invasive Bladder Neoplasms 31Endometrial Neoplasms 30Carcinoma, Hepatocellular 29Sarcoma 28Small Cell Lung Carcinoma 25Head and Neck Neoplasms 25Colonic Neoplasms 19Wilms Tumor 15Metastatic Castration-resistant Prostate Cancer 14Glioblastoma 14Carcinoma, Merkel Cell 14

Interventions

infigratinib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Renal Pelvis and Ureter Urothelial Carcinoma × Genitourinary × Clear all
NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡